2021 / 01

Next Paper
DOI: 10.47183/mes.2021.003

REVIEW

Modern methods for analysis of changes to epigenetic landscape caused by exposure to environmental pollutants

Zanyatkin IA, Titova AG, Bayov AV
About authors

Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency, Moscow, Russia

Correspondence should be addressed: Ivan A. Zanyatkin
Shchukinskaya, 5, str. 6, k. 323, Moscow, 123182; ur.zmpsc@niktaynaZI

About paper

Author contribution: Zanyatkin IA systematized literature data and wrote the manuscript; Titova AG provided additional literature for the review and edited the manuscript; Bayov AV edited the manuscript.

Received: 2020-12-23 Accepted: 2021-01-26 Published online: 2021-02-10
|
  1. Hiragami-Hamada K, et al. The molecular basis for stability of heterochromatin-mediated silencing in mammals. Epigenetics Chromatin. 2009; 2 (1): 14.
  2. Bernstein E, et al. A phosphorylated subpopulation of the histone variant macroH2A1 is excluded from the inactive X chromosome and enriched during mitosis. Proc Natl Acad Sci USA. 2008 Feb 5; 105 (5): 1533–8.
  3. Hartley PD, Madhani HD. Mechanisms that Specify Promoter Nucleosome Location and Identity. Cell. 2009; 137 (3): 445–58.
  4. Jing H, et al. Exchange of GATA Factors Mediates Transitions in Looped Chromatin Organization at a Developmentally Regulated Gene Locus. Molecular Cell. 2008; 29 (2): 232–42.
  5. Klose RJ, Bird AP. Genomic DNA methylation: The mark and its mediators. Trends in Biochemical Sciences. 2006. DOI: 10.1016/J.TIBS.2005.12.008.
  6. Roy D, Yu K, Lieber MR. Mechanism of R-Loop Formation at Immunoglobulin Class Switch Sequences. Mol Cell Biol. 2008 Jan; 28 (1): 50–60.
  7. Beiter T, et al. Antisense transcription: A critical look in both directions. Cell Mol Life Sci. 2009 Jan; 66 (1): 94–112.
  8. Gore AC, et al. EDC-2: The Endocrine Society’s Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocrine Reviews. Endocrine Society. 2015; 36 (6): 1–150.
  9. Subramaniam D, et al. DNA Methyltransferases: A Novel Target for Prevention and Therapy. Front Oncol. 2014; 4: 80.
  10. Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013; 502 (7472): 472–79.
  11. Gillette TG, Hill JA. Readers, writers, and erasers: Chromatin as the whiteboard of heart disease. Circulation Research. 2015; 116 (7): 1245–53.
  12. Sofronov GA, Patkin EL. Jepigeneticheskaja toksikologija: perspektivy razvitija. Toksikologicheskij vestnik. 2018; 0 (1): 2–7. Russian.
  13. Anglim PP, et al. Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer. Mol Cancer. 2008; 7: 62.
  14. Hooven LA, Baird WM. Proteomic analysis of MCF-7 cells treated with benzo[a]pyrene, dibenzo[a,l]pyrene, coal tar extract, and diesel exhaust extract. Toxicology. 2008; 249 (1): 1–10.
  15. Méplan C, Mann K, Hainaut P. Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in cultured cells. J Biol Chem. 1999; 274 (44): 31663–70.
  16. Thompson RF, et al. Experimental intrauterine growth restriction induces alterations in DNA methylation and gene expression in pancreatic islets of rats. J Biol Chem. 2010; 285 (20): 15111–8.
  17. Lister R, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009; 462 (7271): 315–22.
  18. Meissner A, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature. 2008; 454 (7205): 766–70.
  19. Suzuki M, et al. Optimized design and data analysis of tag-based cytosine methylation assays. Genome Biol. 2010; 1 (4): R36.
  20. Ball MP et, al. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol. 2009; 27 (4): 361–8.
  21. Down TA, et al. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nat Biotechnol. 2008; 26 (7): 779–85.
  22. Bibikova M, et al. High density DNA methylation array with single CpG site resolution. Genomics. 2011; 98 (4): 288–95.
  23. Nagalakshmi U, et al. The transcriptional landscape of the yeast genome defined by RNA sequencing. Science. 2008; 320 (5881): 1344–9.
  24. Mikkelsen TS, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature. 2007; 448 (7153): 553–60.
  25. Song L, Crawford GE. DNase-seq: A high-resolution technique for mapping active gene regulatory elements across the genome from mammalian cells. Cold Spring Harb Protoc. 2010; 5 (2): pdb. prot5384.
  26. Fakhrai-Rad H, Pourmand N, Ronaghi M. PyrosequencingTM: An accurate detection platform for single nucleotide polymorphisms. Human Mutation. 2002; 19 (5): 479–85.
  27. De Bustos C, et al. Tissue-specific variation in DNA methylation levels along human chromosome 1. Epigenetics Chromatin. 2009; 2 (1): 7.
  28. Christensen BC, et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CPG island context. PLoS Genet. 2009; 5 (8): e1000602.
  29. Ma X, Chen J, Tian Y. Pregnane X receptor as the sensor and effector in regulating epigenome. J Cell Physiol. 2015; 230 (4): 752–7.
  30. Peters AH, et al. Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin. Nat Genet. 2002; 30 (1): 77–80.
  31. Vakoc CR, et al. Histone H3 lysine 9 methylation and HP1γ are associated with transcription elongation through mammalian chromatin. Mol Cell. 2005; 19 (3): 381–91.
  32. Tilgner H. et al. Nucleosome positioning as a determinant of exon recognition. Nat Struct Mol Biol. 2009; 16 (9): 996–1001.
  33. Laurent L, et al. Dynamic changes in the human methylome during differentiation. Genome Res. 2010; 20 (3): 320–31.
  34. Hou Lifang, et al. Environmental Chemical Exposures and Human Epigenetics. Int J Epidemiol. 2012; 41 (1): 79–105.
  35. Simmons R. Perinatal Programming of Obesity. Semin Perinatol. 2008; 32 (5): 371–4.
  36. Gluckman PD, Hanson MA. Living with the past: Evolution, development, and patterns of disease. Science. 2004; 305 (691): 1733–6.
  37. Derghal A, et al. An emerging role of micro-RNA in the effect of the endocrine disruptors. Front Neurosci. 2016; 10: 318.
  38. Doherty LF, et al. In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: An epigenetic mechanism linking endocrine disruptors to breast cancer. Horm Cancer. 2010; 1 (3): 146–55.
  39. Ernst J, Kellis M. Discovery and characterization of chromatin states for systematic annotation of the human genome. Nat Biotechnol. 2010; 28 (8): 817–25.
  40. LeBaron MJ, et al. Epigenetics and chemical safety assessment. Mutat Res. 2010; 705 (2): 83–95.
  41. Jay IG, et al. What Do We Need to Know Prior to Thinking About Incorporating an Epigenetic Evaluation Into Safety Assessments? Toxicol Sci. 2010; 116 (2): 375–81.
  42. Wild L, et al. In vitro transformation of mesenchymal stem cells induces gradual genomic hypomethylation. Carcinogenesis. 2010; 31(10): 1854–62.
  43. He Y, et al. Spatiotemporal DNA methylome dynamics of the developing mouse fetus: 7818. Nature. 2020; 583 (7818): 752–9.
  44. Anway M, Cupp A, Uzumcu M. Epigenetic Transgenerational Actions of Endocrine Disruptors and Male Fertility. Science. 2005; 308 (5727): 1466–9.
  45. Anway MD, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors. Endocrinology. 2006; 147 (6 Suppl): S43–9.
  46. Crews D, et al. Transgenerational epigenetic imprints on mate preference. Proc Natl Acad Sci USA. 2007; 104 (14): 5942–6.
  47. Guerrero-Bosagna CM, Skinner MK. Epigenetic transgenerational effects of endocrine disruptors on male reproduction. Semin Reprod Med. 2009; 27 (5): 403–8.
  48. Dolinoy DC, Huang D, Jirtle RL. Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc Natl Acad Sci USA. 2007; 104 (32): 13056–61.
  49. Rosenfeld CS, et al. Maternal exposure to bisphenol A and genistein has minimal effect on A vy/a offspring coat color but favors birth of agouti over nonagouti mice. Proc Natl Acad Sci USA. 2013; 110 (2): 537–42.
  50. Udvadia AJ, Linney E. Windows into development: Historic, current, and future perspectives on transgenic zebrafish. Dev Biol. 2003; 256 (1): 1–17.
  51. Krauss V, Reuter G. DNA Methylation in drosophila-a critical evaluation. Prog Mol Biol Transl Sci. 2011; 101: 177–91.
  52. Se K, et al. Sperm Epimutation Biomarkers of Obesity and Pathologies Following DDT Induced Epigenetic Transgenerational Inheritance of Disease. Environ Epigenet. 2019; 5 (2): dvz008
  53. Skrjabin NA, i dr. Metody issledovanija metilirovanija DNK: vozmozhnosti i perspektivy ispol'zovanija v onkologii. Sibirskij Onkologicheskij Zhurnal. 2013; 6. Russian.
  54. Pandey M, Shukla S, Gupta S. Promoter demethylation and chromatin remodeling by green tea polyphenols leads to reexpression of GSTP1 in human prostate cancer cells. Int J Cancer. 2010; 126 (11): 2520–33.
  55. Fang M, Chen D, Yang CS. Dietary Polyphenols May Affect DNA Methylation. J Nutr. 2007; 137 (1 Suppl): 223S–228S.
  56. Won JL, Shim JY, Zhu BT. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol Pharmacol. 2005; 68 (4): 1018–30.
  57. Gao Z, et al. Promoter demethylation of WIF-1 by epigallocatechin3-gallate in lung cancer cells. Anticancer Res. 2009; 29 (6): 2025–30.
  58. FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma. Oncologist. 2007; 12 (10): 1247–52.
  59. Bubna AK. Vorinostat — An Overview. Indian J Dermatol. 2015; 60 (4): 419.
  60. Beaver LM, et al. 3,3’-Diindolylmethane, but not indole-3carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol Appl Pharmacol. 2012; 263 (3): 345–51.
  61. Goon P, Sonnex C, Jani P, et al. Recurrent respiratory papillomatosis: an overview of current thinking and treatment. Eur Arch Otorhinolaryngol. 2008; 265: 147–51.
  62. Rajendran P, et al. Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin Epigenetic. 2011; 3 (1): 4.
  63. Zhang WW, Feng Z, Narod SA. Multiple therapeutic and preventive effects of 3,3′-diindolylmethane on cancers including prostate cancer and high grade prostatic intraepithelial neoplasia. J Biomed Res. 2014; 28 (5): 339–48.
  64. Fan S, et al. DIM (3,3'-diindolylmethane) confers protection against ionizing radiation by a unique mechanism. Proc Natl Acad Sci USA. 2013; 110 (46): 18650–5.
  65. Lyn-Cook BD, Mohammed SI, et al. Gender differences in gemcitabine (Gemzar) efficacy in cancer cells: effect of indole-3carbinol. Anticancer Res. 2010; 30 (12): 4907–13.
  66. Auborn KJ, et al. Lifespan Is Prolonged in Autoimmune-Prone (NZB/NZW) F1 Mice Fed a Diet Supplemented with Indole-3Carbinol. J Nutr Oxford Academic. 2003; 133 (11): 3610–3.
  67. Italiano A, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018; 19 (5): 649–59.
  68. Campbell CT, et al. Mechanisms of Pinometostat (EPZ-5676) Treatment–Emergent Resistance in MLL-Rearranged Leukemia. Mol Cancer Ther. 2017; 16 (8): 1669–79.
  69. Siu LL, Rasco DW, Vinay SP, et al. METEOR-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours. Ann Oncol. 2019; 30 (Suppl 5): v159–v193.
  70. Claus R, Lübbert M. Epigenetic targets in hematopoietic malignancies. Oncogene. 2003; 22 (42): 6489–96.
  71. Pogribny IP, Tryndyak VP, Boureiko A, Melnyk S, Bagnyukova TV, Montgomery B, et al. Mechanisms of peroxisome proliferatorinduced DNA hypomethylation in rat liver. Mutat Res. 2008; 644 (1–2): 17–23.
  72. Niculescu MD, Zeisel SH. Diet, methyl donors and DNA methylation: interactions between dietary folate, methionine and choline. J Nutr. 2002; 132 (8 Suppl): 2333S–5S.
  73. Verma S, et al. Computational approaches in epitope design using DNA binding proteins as vaccine candidate in Mycobacterium tuberculosis. Infect Genet Evol. 2020; 83: 1348–1567.